New Series of Pyrazoles and Imidazo-Pyrazoles Targeting Different Cancer and Inflammation Pathways

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Biology

Background:

• Previously synthesized pyrazoles and imidazo-pyrazoles demonstrated anti-angiogenic properties.
• These compounds interfered with signaling pathways like ERK1/2, AKT, and p38MAPK phosphorylation.

Purpose of the Study:

• Synthesize a new library of pyrazole and imidazo-pyrazole derivatives.
• Develop novel agents targeting pathways in inflammation, cancer, and platelet aggregation.
• Evaluate the anti-angiogenic potential of newly synthesized compounds.

Main Methods:

• Chemical synthesis of a new library of decorated pyrazole and imidazo-pyrazole scaffolds.
• Assessment of compound activity in blocking reactive oxygen species (ROS) production.
• Evaluation of inhibition of platelet aggregation.
• Analysis of p38MAPK phosphorylation in platelets and Human Umbilical Vein Endothelial cells (HUVEC).

Main Results:

• Most synthesized derivatives effectively blocked ROS production.
• Significant inhibition of platelet aggregation was observed.
• p38MAPK phosphorylation was inhibited in both platelets and HUVECs.
• The compounds show promise as anti-angiogenic agents.

Conclusions:

• The novel pyrazole and imidazo-pyrazole derivatives exhibit potent anti-inflammatory and anti-cancer properties.
• These compounds effectively inhibit key pathways involved in angiogenesis, inflammation, and thrombosis.
• The findings support the development of these agents for therapeutic applications in cancer and inflammatory diseases.